Drugs

Low levels of the naturally occurring, soft shiny metal could reduce violence and enhance moods for all.

As Western medicine brings psychedelics into mainstream use, a growing movement is innovating new business models grounded in reciprocity and inclusion.

Syncing cures with circadian rhythms is an idea whose moment has finally come.

Space brain and other cosmic problems demand new kinds of pharmaceutical protection.

Gene tests for antidepressants are going mainstream — and getting more confusing. Here’s a guide.

Soon, precision medicine could help you avoid expensive, risky procedures that you may not need.

There’s gold in your gut—and startups are mining it with microbiome science. The biggest hurdle? Stool doesn’t scale.

Since he was a child, James Peyer has been obsessed with stopping aging. Now he has a fund — and a plan.

Sara Riggare can’t finish her PhD because an ethics committee says she needed their approval first.

“I’m just a girl living with type 1 diabetes who got tired of waiting.”

After watching medical records get traded for billions of dollars, a tech entrepreneur says he can help you grab a share of the bounty.

It’s made out of living human cells. Someday they could be yours.

Investors and families are counting on Onno Faber to galvanize research into neglected conditions—like the one threatening his hearing and sight.

Michael Pollan explores the neuroscience of psychedelics in this excerpt from his new book.

Billionaire Jim Mellon bets that a “stock market mania” will be sparked by technologies that make people live past 100.